CYANOTECH CORP (NASDAQ:CYAN) net profit margin is 9.50% and weekly performance is -5.15%. On last trading day company shares ended up $4.60. Analysts mean target price for the company is $14.00. CYANOTECH CORP (NASDAQ:CYAN) distance from 50-day simple moving average (SMA50) is -7.65%.
On 2 JUNE Lpath, Inc. (NASDAQ:LPTN) said it will present a Trial-in-Progress poster at the American Society of Clinical Oncology (ASCO) meeting in Chicago. Lpath, Inc. (NASDAQ:LPTN) shares fell -1.59% in last trading session and ended the day on $3.72. LPTN return on assets is -45.60%. Lpath, Inc. (NASDAQ:LPTN) quarterly performance is -23.30%.
On 16 MAY Sophiris Bio Inc (NASDAQ:SPHS) reported ($0.52) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.50) by $0.02. On average, analysts predict that Sophiris Bio will post $-1.84 earnings per share for the current fiscal year. Sophiris Bio Inc (NASDAQ:SPHS) shares moved down -6.99% in last trading session and was closed at $2.40, while trading in range of $2.25 – $2.88. Sophiris Bio Inc (NASDAQ:SPHS) year to date (YTD) performance is -35.14%.
On 4 JUNE K2M Group Holdings Inc (NASDAQ:KTWO) reported financial results for the three months ended March 31, 2014. Total revenue of $42.3 million, up 20.4% year-over-year
International revenue of $12.5 million, up 34.8% year-over-year. Domestic revenue of $29.8 million, up 15.2% year-over-year. Expands Minimally Invasive Portfolio with 510(k) Clearance of CAYMAN®. K2M Group Holdings Inc (NASDAQ:KTWO) ended the last trading day at $14.60. Company weekly volatility is calculated as 5.13%. K2M Group Holdings Inc (NASDAQ:KTWO) showed a negative weekly performance of -2.34%.
On 29 MAY KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) said it has seen two positive estimate revisions in the last 30 days. The Zacks Consensus Estimate has also moved higher over the same period. This implies solid trading potential for the company. KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) weekly performance is -7.45%. On last trading day company shares ended up $1.74. Analysts mean target price for the company is $7.50. KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) distance from 50-day simple moving average (SMA50) is -20.69%.